Clinical Trials Environment Is Appealing But Attractiveness May Fall Due To Cost Considerations

BMI View: While Israel has historically been a cheap and effective site for clinical trials, it is becoming increasingly expensive compared to emerging markets and it also cannot compete with their large populations, which are increasingly attractive for clinical research organisations (CROs). That said, the country has good regulatory and academic credentials and we believe it will continue to be preferred for more early-stage clinical

To read the full article, please choose one of the following options: